{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:36:52Z","timestamp":1786711012716,"version":"build-2736575974"},"reference-count":205,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brain tumors in infants represent a rare but clinically challenging subset of pediatric central nervous system (CNS) neoplasms. These tumors are biologically and clinically distinct from those in older children and adults, with a predilection for supratentorial locations, frequent presentation with macrocephaly and signs of increased intracranial pressure, and unique molecular profiles. There have been many advances in molecular profiling, now influencing treatment choice and outcomes. Non-embryonal tumor types\u2014including glial tumors, choroid plexus tumors, craniopharyngioma, ependymoma, teratoma, and germ cell tumors\u2014collectively constitute the majority of infant brain tumors and warrant focused attention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and scope<\/jats:title>\n                    <jats:p>This review synthesizes the current literature on the epidemiology, molecular biology, clinical presentation, management, and outcomes of non-embryonal brain tumors diagnosed in infants (age \u226412-36 months). Tumor types addressed include low-grade and high-grade gliomas (including the recently defined infant-type hemispheric glioma [IHG]), choroid plexus papilloma and carcinoma, ependymoma, craniopharyngioma, teratoma, and intracranial germ cell tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Glial tumors are among the most common infant brain tumors, with low-grade gliomas demonstrating excellent survival approaching 100%, while high-grade gliomas carry a significantly worse prognosis. IHGs are a molecularly distinct entity driven by receptor tyrosine kinase (RTK) fusions involving ALK, NTRK1\/2\/3, ROS1, and MET, with three-year overall survival of approximately 80% and emerging evidence supporting targeted tyrosine kinase inhibitor therapy. Choroid plexus papillomas peak during infancy and are curable with gross total resection, whereas choroid plexus carcinomas have five-year survival rates of 61\u201365% and require multimodal therapy. Posterior fossa A (PFA) ependymomas predominate in infants and behave more aggressively than other ependymoma subtypes. Craniopharyngiomas, though rare in infancy, present unique surgical challenges given their proximity to the hypothalamic-pituitary axis. Intracranial teratomas are the most common congenital brain tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non-embryonal infant brain tumors encompass a heterogeneous group of neoplasms with widely variable outcomes. Advances in molecular classification\u2014particularly the identification of targetable RTK fusions in IHG\u2014are reshaping therapeutic paradigms. Integrated histopathologic and molecular characterization per the WHO CNS5 classification is essential for accurate diagnosis and optimal treatment planning in this vulnerable population. Collaborative, prospective studies are needed to establish standardized treatment approaches and improve long-term neurocognitive outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1874371","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:58:06Z","timestamp":1786708686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Report from the National Pediatric Cancer Foundation - infantile glioma and other non-embryonal central nervous system tumors: evolving molecular advances and current treatment landscape"],"prefix":"10.3389","volume":"16","author":[{"given":"Evan","family":"Cantor","sequence":"first","affiliation":[{"name":"University of Connecticut School of Medicine","place":["Farmington, CT, United States"]},{"name":"Department of Pediatrics, Connecticut Children\u2019s Medical Center","place":["Hartford, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Qutob","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Connecticut Children\u2019s Medical Center","place":["Hartford, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Ayers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Connecticut Children\u2019s Medical Center","place":["Hartford, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan","family":"Donnville","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Connecticut Children\u2019s Medical Center","place":["Hartford, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nieves","sequence":"additional","affiliation":[{"name":"Arnold Palmer Hospital for Children","place":["Orlando, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cruz-Flores","sequence":"additional","affiliation":[{"name":"Division of Oncology, Johns Hopkins All Children\u2019s Hospital","place":["St. Petersburg, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Stapleton","sequence":"additional","affiliation":[{"name":"Division of Oncology, Johns Hopkins All Children\u2019s Hospital","place":["St. Petersburg, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21351","article-title":"Tumors of the central nervous system in the first years of life","volume":"49","author":"Larouche","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","article-title":"CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/bf00706804","article-title":"Congenital intracranial neoplasms","volume":"2","author":"Ellams","year":"1986","journal-title":"Child's Nervous System"},{"key":"B4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0090-3019(84)90277-5","article-title":"Congenital brain tumors","volume":"21","author":"Wakai","year":"1984","journal-title":"Surg Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/10935266211009101","article-title":"Pediatric glial tumors","volume":"25","author":"Viaene","year":"2022","journal-title":"Pediatr Dev Pathol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00004728-198801000-00002","article-title":"Neonatal brain tumors: CT and MR findings","volume":"12","author":"Radkowski","year":"1988","journal-title":"J Comput Assist Tomogr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.155.3.2167004","article-title":"Congenital brain tumors: a review of 45 cases","volume":"155","author":"Buetow","year":"1990","journal-title":"AJR Am J Roentgenol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807308692","article-title":"Brain tumors in children: initial symptoms and their influence on the time span between symptom onset and diagnosis","volume":"23","author":"Reulecke","year":"2008","journal-title":"J Child Neurol"},{"key":"B9","article-title":"Tumors of the fetus and newborn","volume":"45","author":"Isaacs","year":"1997"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-199010000-00001","article-title":"Prenatal diagnosis of fetal tumors by ultrasonography","volume":"45","author":"Wienk","year":"1990","journal-title":"Obstetrical Gynecological Survey"},{"key":"B11","article-title":"Congenital brain tumors","volume":"2","author":"Raisanen","year":"1993","journal-title":"Pathol (Philadelphia Pa)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf087","article-title":"Co-occurrence of congenital anomalies and childhood brain tumors in 22 million live births","volume":"27","author":"Hoang","year":"2025","journal-title":"Neuro-oncology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/bf01809448","article-title":"Brain tumours under the age of three. The price of survival. A retrospective study of 20 long-term survivors","volume":"106","author":"Suc","year":"1990","journal-title":"Acta Neurochir (Wien)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.01.214","article-title":"Intellectual and functional outcome of children 3 years old or younger who have CNS Malignancies","volume":"23","author":"Fouladi","year":"2005","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.12.3720","article-title":"Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital","volume":"17","author":"Walter","year":"1999","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-911x(199705)28:5<348::aid-mpo4>3.0.co;2-h","article-title":"Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old","volume":"28","author":"Kiltie","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.01.202","article-title":"Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study","volume":"21","author":"Packer","year":"2003","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.11.3476","article-title":"Neurocognitive development of children after a cerebellar tumor in infancy: A longitudinal study","volume":"17","author":"Copeland","year":"1999","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851101)56:9<2189::aid-cncr2820560909>3.0.co;2-i","article-title":"Long-term effects of cranial irradiation on endocrine function in children with brain tumors. A prospective study","volume":"56","author":"Duffner","year":"1985","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00046-6","article-title":"Variation in survival of children with central nervous system (CNS) Malignancies diagnosed in Europe between 1978 and 1992: the EUROCARE study","volume":"37","author":"Magnani","year":"2001","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12656","article-title":"The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes","volume":"47","author":"Hicks","year":"2021","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-04655-x","article-title":"Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome","volume":"36","author":"J\u00fcnger","year":"2020","journal-title":"Childs Nerv Syst"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-1030","article-title":"Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes","volume":"10","author":"Clarke","year":"2020","journal-title":"Cancer Discov"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18478","article-title":"High-grade glioma in very young children: a rare and particular patient population","volume":"8","author":"El-Ayadi","year":"2017","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-03967-z","article-title":"Population-based analysis of CNS tumor diagnoses, treatment, and survival in congenital and infant age groups","volume":"157","author":"Hart","year":"2022","journal-title":"J Neuro-Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05404-3","article-title":"Central nervous system tumours in neonates: what should the neonatologist know","volume":"183","author":"Toniutti","year":"2024","journal-title":"Eur J Pediatr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2019.01.006","article-title":"Management of fetal tumors","volume":"58","author":"Masmejan","year":"2019","journal-title":"Best Pract Res Clin Obstetrics Gynaecology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2016.1205029","article-title":"Fetal intracranial immature teratoma: presentation of a case and a systematic review of the literature","volume":"30","author":"Robles Fradejas","year":"2017","journal-title":"J Maternal-Fetal Neonatal Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.641","article-title":"BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors","volume":"7","author":"Breton","year":"2017","journal-title":"Brain Behav"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001571","article-title":"Correlation between immunohistochemistry and sequencing in H3G34-mutant gliomas","volume":"45","author":"Gianno","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26430","article-title":"Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes","volume":"9","author":"Huang","year":"2018","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1752-4","article-title":"Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome","volume":"134","author":"Panwalkar","year":"2017","journal-title":"Acta Neuropathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab227","article-title":"Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics","volume":"24","author":"Wu","year":"2022","journal-title":"Neuro Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/cco.0000000000000223","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1311","article-title":"Liquid biopsy: From discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac035","article-title":"Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients","volume":"24","author":"Miller","year":"2022","journal-title":"Neuro Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab299","article-title":"Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine","volume":"24","author":"Pag\u00e8s","year":"2022","journal-title":"Neuro Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04645-y","article-title":"Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors","volume":"168","author":"Ronsley","year":"2024","journal-title":"J Neuro-Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","article-title":"Serial assessment of measurable residual disease in medulloblastoma liquid biopsies","volume":"39","author":"Liu","year":"2021","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"14326","DOI":"10.1038\/s41598-020-71161-0","article-title":"Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors","volume":"10","author":"Takayasu","year":"2020","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s40478-024-01886-w","article-title":"High detection rate of circulating-tumor DNA from cerebrospinal fluid of children with central nervous system germ cell tumors","volume":"12","author":"Nakano","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-026-01115-4","article-title":"M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors","volume":"7","author":"Smith","year":"2026","journal-title":"Nat Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.12.011","article-title":"Infant brain tumors: a neuropathologic population-based institutional reappraisal","volume":"43","author":"Dunham","year":"2012","journal-title":"Hum Pathol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3109\/08880010903447342","article-title":"Central nervous system (CNS) tumors in the first six months of life: the Childrens Hospital Los Angeles Experience, 1979\u20132005","volume":"27","author":"Serowka","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24729","article-title":"Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG)","volume":"61","author":"Mirow","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos202","article-title":"Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology","volume":"14","author":"Gnekow","year":"2012","journal-title":"Neuro Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.12.008","article-title":"Phase II study of carboplatin in children with progressive low-grade gliomas","volume":"20","author":"Gururangan","year":"2002","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00590","article-title":"Midline low-grade gliomas of early childhood: focus on targeted therapies","volume":"8","author":"Papusha","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0b013e318214a66e","article-title":"Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group","volume":"68","author":"Wisoff","year":"2011","journal-title":"Neurosurgery"},{"key":"B52","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group","volume":"30","author":"Ater","year":"2012","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u2264 16 years) low grade glioma\u2013a final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29711","article-title":"Single agent carboplatin for pediatric low-grade glioma: a retrospective analysis shows equivalent efficacy to multiagent chemotherapy","volume":"138","author":"Dodgshun","year":"2016","journal-title":"Int J Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.428","article-title":"LGG-37. A phase III study comparing two carboplatin containing regimens for children and young adults with previously untreated low-grade glioma","volume":"26","author":"Lenen","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma","volume":"30","author":"Bouffet","year":"2012","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21091","article-title":"Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction","volume":"103","author":"Lafay-Cousin","year":"2005","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33170","article-title":"Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low\u2010grade glioma patients\u2014report from the German SIOP\u2010LGG 2004 cohort","volume":"147","author":"Kandels","year":"2020","journal-title":"Int J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor090","article-title":"A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study","volume":"13","author":"Jakacki","year":"2011","journal-title":"Neuro-oncology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2006-030","article-title":"Temozolomide in children with progressive low-grade glioma","volume":"9","author":"Gururangan","year":"2007","journal-title":"Neuro-oncology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-7216-8148-1.50088-7","article-title":"Desmoplastic infantile ganglioglioma","volume":"19","author":"Tamburrini","year":"2003","journal-title":"Child's Nervous System"},{"key":"B63","first-page":"99","article-title":"Desmoplastic infantile astrocytoma and ganglioglioma","volume":"2000","author":"Taratuto","year":"2000","journal-title":"Pathol Genet Tumors Nervous System"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-003-0754-9","article-title":"Therapeutic strategies and management of desmoplastic infantile ganglioglioma: two case reports and literature overview","volume":"19","author":"B\u00e4chli","year":"2003","journal-title":"Child's Nervous System"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-17-0507","article-title":"Desmoplastic infantile ganglioglioma\/astrocytoma (DIG\/DIA) are distinct entities with frequent BRAFV600 mutations","volume":"16","author":"Wang","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/(sici)1096-8628(19990326)89:1<38::aid-ajmg8>3.0.co;2-m","article-title":"Intracranial gliomas in neurofibromatosis type 1","volume":"89","author":"Listernick","year":"1999","journal-title":"Am J Med Genet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(89)80137-4","article-title":"Optic gliomas in children with neurofibromatosis type 1","volume":"114","author":"Listernick","year":"1989","journal-title":"J Pediatr"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(94)70122-9","article-title":"Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study","volume":"125","author":"Listernick","year":"1994","journal-title":"J Pediatr"},{"key":"B69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-010-0159-z","article-title":"Natural history and management of low-grade glioma in NF-1 children","volume":"100","author":"Hern\u00e1iz Driever","year":"2010","journal-title":"J Neuro-Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/9780470987148.ch8","article-title":"Non-randomized comparison between neurofibromatosis type 1 (NF1) and non-NF1 children who received carboplatin and vincristine (CV) for progressive low grade glioma (LGG): a report from the Children\u2019s Oncology Group (COG)","volume":"122","author":"Ater","year":"2016","journal-title":"Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1\u2013associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro-oncology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac223","article-title":"A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: safety, efficacy, visual morbidity, and outcomes","volume":"25","author":"Green","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not154","article-title":"Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2014a Pediatric Brain Tumor Consortium study","volume":"16","author":"Gururangan","year":"2014","journal-title":"Neuro-oncology"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.22541\/au.168069089.92810228\/v1","article-title":"Visual outcomes after bevacizumab\u2010based therapy for optic pathway glioma","volume":"70","author":"Siegel","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq007","article-title":"Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas","volume":"12","author":"Dougherty","year":"2010","journal-title":"Neuro-oncology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/jci33656","article-title":"BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas","volume":"118","author":"Pfister","year":"2008","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/nen.0b013e3181845622","article-title":"Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma","volume":"67","author":"Bar","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac241","article-title":"The clinical and molecular characteristics of progressive hypothalamic\/optic pathway pilocytic astrocytoma","volume":"25","author":"Li","year":"2023","journal-title":"Neuro-oncology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1300252110","article-title":"Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1","volume":"110","author":"Ramkissoon","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-010-0763-1","article-title":"MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas","volume":"120","author":"Tatevossian","year":"2010","journal-title":"Acta Neuropathol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1066","article-title":"Analysis of pilocytic astrocytoma by comparative genomic hybridization","volume":"82","author":"Sanoudou","year":"2000","journal-title":"Br J Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/01.jnen.0000240465.33628.87","article-title":"Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age","volume":"65","author":"Jones","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32995","article-title":"Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO\u2010grade II\u2014report from the German\/Swiss SIOP\u2010LGG 2004 cohort","volume":"147","author":"Falkenstein","year":"2020","journal-title":"Int J Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.71.8726","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1120-y","article-title":"BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma","volume":"125","author":"Dahiya","year":"2013","journal-title":"Acta Neuropathol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae048","article-title":"Comprehensive analysis of MYB\/MYBL1-altered pediatric-type diffuse low-grade glioma","volume":"26","author":"Moreira","year":"2024","journal-title":"Neuro-oncology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro-oncology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600\u2013mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.17_suppl.lba2002","article-title":"Primary analysis of a phase II trial of dabrafenib plus trametinib (dab+ tram) in BRAF V600\u2013mutant pediatric low-grade glioma (pLGG)","author":"Bouffet","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03592-8","article-title":"Trametinib for the treatment of recurrent\/progressive pediatric low-grade glioma","volume":"149","author":"Manoharan","year":"2020","journal-title":"J Neuro-Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2971-9","article-title":"Trametinib for progressive pediatric low-grade gliomas","volume":"140","author":"Kondyli","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-020-03640-3","article-title":"Response to trametinib treatment in progressive pediatric low-grade glioma patients","volume":"149","author":"Selt","year":"2020","journal-title":"J Neuro-Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac079.716","article-title":"LTBK-04. Late breaking abstract: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study","volume":"24","author":"Robison","year":"2022","journal-title":"Neuro-Oncology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00888-9","article-title":"Cobimetinib in pediatric and young adult patients with relapsed or refractory solid tumors (iMATRIX-cobi): a multicenter, phase I\/II study","volume":"17","author":"Trippett","year":"2022","journal-title":"Targeted Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"viii113","DOI":"10.1093\/neuonc\/noae165.0437","article-title":"Ctni-70. Results from the phase 1 and phase 1 expansion cohorts of sj901: A phase 1\/2 trial of single-agent mirdametinib (pd-0325901) in children, adolescents, and young adults with low-grade glioma","volume":"26","author":"Robinson","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: The phase 2 firefly-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12885-024-11820-x","article-title":"Loggic\/firefly-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating raf alteration","volume":"24","author":"van Tilburg","year":"2024","journal-title":"BMC Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3439","article-title":"Fda approval summary: Tovorafenib for relapsed or refractory braf-altered pediatric low-grade glioma","volume":"31","author":"Singh","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1038\/s41467-025-61820-z","article-title":"A diverse landscape of fgfr alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas","volume":"16","author":"Apfelbaum","year":"2025","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad073.224","article-title":"Lgg-14. Treatment of two pediatric fgfr-altered low-grade glioneuronal tumors with mek inhibition","volume":"25","author":"Lazow","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3171\/2019.12.jns192155","article-title":"Association of the fgfr1 mutation with spontaneous hemorrhage in low-grade gliomas in pediatric and young adult patients","volume":"134","author":"Ishi","year":"2021","journal-title":"J Neurosurg"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0000000000000213","article-title":"KIAA1549: BRAF gene fusion and fgfr1 hotspot mutations are prognostic factors in pilocytic astrocytomas","volume":"74","author":"Becker","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"B109","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.10007","article-title":"Erdafitinb in patients with fgfr-altered tumors: Results from the nci-cog pediatric match trial arm b (apec1621b)","volume-title":"American Society of Clinical Oncology","author":"Lee","year":"2023"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00444","article-title":"Debio1347, an oral fgfr inhibitor: Results from a single-center study in pediatric patients with recurrent or refractory fgfr-altered gliomas","volume":"5","author":"Farouk Sait","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos125","article-title":"Clinical and molecular characteristics of congenital glioblastoma","volume":"14","author":"Macy","year":"2012","journal-title":"Neuro-oncology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10090648","article-title":"Infantile\/congenital high-grade gliomas: Molecular features and therapeutic perspectives","volume":"10","author":"Ceglie","year":"2020","journal-title":"Diagnostics"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-015-7_8","article-title":"A comprehensive analysis of infantile central nervous system tumors to improve distinctive criteria for infant\u2010type hemispheric glioma versus desmoplastic infantile ganglioglioma\/astrocytoma","volume":"33","author":"Tauzi\u00e8de-Espariat","year":"2023","journal-title":"Brain Pathol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad130","article-title":"High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the sjyc07 trial and institutional experience","volume":"26","author":"Chiang","year":"2024","journal-title":"Neuro-oncology"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199306173282401","article-title":"Postoperative chemotherapy and delayed radiation in children less than three years of age with Malignant brain tumors","volume":"328","author":"Duffner","year":"1993","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq191","article-title":"Temozolomide in the treatment of high-grade gliomas in children: A report from the children's oncology group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro-oncology"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.06.021","article-title":"High-grade glioma in children under 5 years of age: A chemotherapy only approach with the bbsfop protocol","volume":"42","author":"Dufour","year":"2006","journal-title":"Eur J Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","year":"2014","journal-title":"Nat Genet"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007752","article-title":"Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations","volume":"4","author":"Brennan","year":"2009","journal-title":"PloS One"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12210","article-title":"Genetic analysis of diffuse high\u2010grade astrocytomas in infancy defines a novel molecular entity","volume":"25","author":"Gessi","year":"2015","journal-title":"Brain Pathol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.0242","article-title":"Pediatric gliomas: Current concepts on diagnosis, biology, and clinical management","volume":"35","author":"Sturm","year":"2017","journal-title":"J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.26.7252","article-title":"Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease","volume":"28","author":"Paugh","year":"2010","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdz033","article-title":"Constitutional mismatch repair deficiency\u2013associated brain tumors: Report from the european c4cmmrd consortium","volume":"1","author":"Guerrini-Rousseau","year":"2019","journal-title":"Neuro-oncology Adv"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.5728","article-title":"Revisiting li-fraumeni syndrome from tp53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J Clin Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41467-019-12187-5","article-title":"Alterations in alk\/ros1\/ntrk\/met drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin","year":"2019","journal-title":"Nat Commun"},{"key":"B128","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40478-020-00980-z","article-title":"Molecular and clinicopathologic features of gliomas harboring ntrk fusions","volume":"8","author":"Torre","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"B129","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41698-026-01336-x","article-title":"Novel activating snrnp70-alk fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: A case-report","volume":"10","author":"Arthur","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28050284","article-title":"Reflex ros1 ihc screening with fish confirmation for advanced non-small cell lung cancer\u2014a cost-efficient strategy in a public healthcare system","volume":"28","author":"Makarem","year":"2021","journal-title":"Curr Oncol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"817.e5","DOI":"10.1016\/j.wneu.2017.02.026","article-title":"Congenital glioblastoma with distinct clinical and molecular characteristics: Case reports and a literature review","volume":"101","author":"Kameda","year":"2017","journal-title":"World Neurosurg"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7102","article-title":"An infant-type hemispheric glioma with sox5:: alk: A novel fusion","volume":"22","author":"Tsai","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00547","article-title":"Clinical and molecular evolution of an alk-driven infant-type hemispheric glioma treated sequentially with second-and third-generation anaplastic lymphoma kinase inhibitors","volume":"7","author":"Gene-Olaciregui","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1123378","article-title":"Case report: Atic-alk fusion in infant-type hemispheric glioma and response to lorlatinib","volume":"13","author":"Shah","year":"2023","journal-title":"Front Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51766","article-title":"Lorlatinib for alk\u2010fused, infant\u2010type hemispheric glioma with lung metastasis: A case report","volume":"10","author":"Lai","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00255","article-title":"Lorlatinib for the treatment of alk fusion\u2013positive infant-type hemispheric glioma: A case report","volume":"6","author":"Greenwell","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2101264","article-title":"Lorlatinib in a child with alk-fusion\u2013positive high-grade glioma","volume":"385","author":"Bagchi","year":"2021","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02396-y","article-title":"Activating ntrk2 and alk receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: A diagnostic overlap with infant-type hemispheric glioma","volume":"143","author":"Lucas","year":"2022","journal-title":"Acta Neuropathol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02297-5","article-title":"Lorlatinib with or without chemotherapy in alk-driven refractory\/relapsed neuroblastoma: Phase 1 trial results","volume":"29","author":"Goldsmith","year":"2023","journal-title":"Nat Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary cns tumors harboring ntrk, ros1, or alk aberrations (startrk-ng)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro-oncology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac026","article-title":"Two clinically distinct cases of infant hemispheric glioma carrying zcchc8: ros1 fusion and responding to entrectinib","volume":"24","author":"Papusha","year":"2022","journal-title":"Neuro-oncology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in trk fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro-oncology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41416-018-0251-2","article-title":"Brief report: Potent clinical and radiological response to larotrectinib in trk fusion-driven high-grade glioma","volume":"119","author":"Ziegler","year":"2018","journal-title":"Br J Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.162","article-title":"Trls-09. Connect1903: A pilot and surgical study of larotrectinib for treatment of children with newly diagnosed hgg with ntrk fusion (nct04655404)","volume":"26","author":"Chi","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/path.5457","article-title":"Advances in the molecular classification of pediatric brain tumors: A guide to the galaxy","volume":"251","author":"Cacciotti","year":"2020","journal-title":"J Pathol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/nature13109","article-title":"C11orf95\u2013rela fusions drive oncogenic nf-\u03bab signalling in ependymoma","volume":"506","author":"Parker","year":"2014","journal-title":"Nature"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all cns compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12659","article-title":"Childhood supratentorial ependymomas with yap1\u2010mamld1 fusion: An entity with characteristic clinical, radiological, cytogenetic and histopathological features","volume":"29","author":"Andreiuolo","year":"2019","journal-title":"Brain Pathol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13068","article-title":"Updates in the classification of ependymal neoplasms: The 2021 WHO classification and beyond","volume":"32","author":"Kresbach","year":"2022","journal-title":"Brain Pathol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-022-00429-2","article-title":"Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications","volume":"39","author":"Chinnam","year":"2022","journal-title":"Brain Tumor Pathol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10014-020-00385-9","article-title":"EZH2 inhibitory protein (EZHIP\/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations","volume":"38","author":"Nambirajan","year":"2021","journal-title":"Brain Tumor Pathol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab034","article-title":"Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q","volume":"23","author":"Baroni","year":"2021","journal-title":"Neuro-oncology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10014-020-00385-9","article-title":"Correction to: EZH2 inhibitory protein (EZHIP\/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations","volume":"38","author":"Nambirajan","year":"2021","journal-title":"Brain Tumor Pathol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203451","article-title":"H3K27me3 loss in central nervous system tumors: Diagnostic, prognostic, and therapeutic implications","volume":"16","author":"Angelico","year":"2024","journal-title":"Cancers"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.10.033","article-title":"Supratentorial ependymoma: disease control, complications, and functional outcomes after irradiation","volume":"85","author":"Landau","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B156","article-title":"Childhood ependymoma treatment (PDQ\u00ae): treatment-health professional information [NCI","author":"Luthringer","year":""},{"key":"B157","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/neuonc\/noaf285","article-title":"Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group","volume":"28","author":"Smith","year":"2026","journal-title":"Neuro-Oncology"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not163","article-title":"Benefit from prolonged dose-intensive chemotherapy for infants with Malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233\/34","volume":"16","author":"Strother","year":"2014","journal-title":"Neuro-oncology"},{"key":"B159","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/pbc.20935","article-title":"Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue","volume":"49","author":"Zacharoulis","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1111-9","article-title":"Outcome of infants and young children with newly diagnosed ependymoma treated on the \u201cHead Start\u201d III prospective clinical trial","volume":"113","author":"Venkatramani","year":"2013","journal-title":"J Neuro-Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz069","article-title":"Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial","volume":"21","author":"Upadhyaya","year":"2019","journal-title":"Neuro-oncology"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02484-7","article-title":"Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children\u2019s Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials","volume":"144","author":"Liu","year":"2022","journal-title":"Acta Neuropathol"},{"key":"B163","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.10548","article-title":"Outcomes for young children with molecularly defined ependymoma treated on the multi-institutional SJYC07 clinical trial","volume-title":"American Society of Clinical Oncology","author":"Upadhyaya","year":"2018"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100860","article-title":"Primary central nervous system germ cell tumors in children and young adults: A review of controversies in diagnostic and treatment approach","volume":"36","author":"Yeo","year":"2023","journal-title":"Neoplasia"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0037","article-title":"Pediatric central nervous system germ cell tumors: a review","volume":"13","author":"Echevarr\u00eda","year":"2008","journal-title":"Oncologist"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-010-0699-0","article-title":"Congenital tumors of the central nervous system","volume":"52","author":"Severino","year":"2010","journal-title":"Neuroradiology"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/pd.5872","article-title":"Fetal teratomas\u2013A retrospective observational single\u2010center study","volume":"41","author":"Simonini","year":"2021","journal-title":"Prenatal Diagnosis"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51891","article-title":"Large immature intracranial teratoma in an infant: A case report","volume":"16","author":"Da Silva","year":"2024","journal-title":"Cureus"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2011.09.012","article-title":"Surgical treatment of brain tumors in infants younger than six months of age and review of the literature","volume":"78","author":"Lang","year":"2012","journal-title":"World Neurosurg"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14050445","article-title":"CNS germ cell tumors: molecular advances, significance in risk stratification and future directions","volume":"14","author":"Zhou","year":"2024","journal-title":"Brain Sci"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/nature13296","article-title":"Novel somatic and germline mutations in intracranial germ cell tumours","volume":"511","author":"Wang","year":"2014","journal-title":"Nature"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-00953-2","article-title":"Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients","volume":"8","author":"Guntner","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12570","article-title":"Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance","volume":"46","author":"Takami","year":"2020","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.paed.2009.10.006","article-title":"Germ cell tumours in children and adolescents","volume":"20","author":"Murray","year":"2010","journal-title":"Paediatrics Child Health"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3171\/2019.10.focus19705","article-title":"Adamantinomatous craniopharyngioma: moving toward targeted therapies","volume":"48","author":"Hengartner","year":"2020","journal-title":"Neurosurgical Focus"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab397","article-title":"Childhood-onset craniopharyngioma","volume":"106","author":"Otte","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B177","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3171\/jns.1980.52.1.0036","article-title":"Management of the unresectable cystic craniopharyngioma by aspiration through an Ommaya reservoir drainage system","volume":"52","author":"Gutin","year":"1980","journal-title":"J Neurosurg"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-04677-5","article-title":"Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: a review","volume":"36","author":"Whelan","year":"2020","journal-title":"Child's Nervous System"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020723","article-title":"Advancing craniopharyngioma management: a systematic review of current targeted therapies and future perspectives","volume":"25","author":"Agosti","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000600","article-title":"The molecular pathogenesis of craniopharyngiomas","volume":"67","author":"Campanini","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy035","article-title":"Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma","volume":"20","author":"Coy","year":"2018","journal-title":"Neuro-oncology"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1297132","article-title":"Childhood craniopharyngioma: a retrospective study of children followed in H\u00f4pital Universitaire de Bruxelles","volume":"15","author":"Magerman","year":"2024","journal-title":"Front Endocrinol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1111\/cen.70103","article-title":"Pediatric and adult craniopharyngioma: A 37-year experience at a national referral center","volume":"104","author":"Hern\u00e1ndez","year":"2026","journal-title":"Clin Endocrinol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf651","article-title":"Arginine vasopressin deficiency and oxytocin deficiency in the endocrine clinic","volume":"111","author":"Atila","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B185","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40644-019-0200-1","article-title":"Choroid plexus tumours on MRI: similarities and distinctions in different grades","volume":"19","author":"Lin","year":"2019","journal-title":"Cancer Imaging"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1616-x","article-title":"Choroid plexus tumor epidemiology and outcomes: implications for surgical and radiotherapeutic management","volume":"121","author":"Cannon","year":"2015","journal-title":"J Neuro-Oncol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2561-2","article-title":"A French retrospective study on clinical outcome in 102 choroid plexus tumors in children","volume":"135","author":"Siegfried","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23349","article-title":"Choroid plexus tumors; management, outcome, and association with the Li\u2013Fraumeni syndrome: The Children's Hospital Los Angeles (CHLA) experience, 1991\u20132010","volume":"58","author":"Gozali","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/jco.2009.26.8169","article-title":"TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors","volume":"28","author":"Tabori","year":"2010","journal-title":"J Clin Oncol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac274","article-title":"Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis","volume":"25","author":"Zaytseva","year":"2023","journal-title":"Neuro-oncology"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3171\/2010.3.peds09354","article-title":"Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma","volume":"5","author":"Lafay-Cousin","year":"2010","journal-title":"J Neurosurgery: Pediatr"},{"key":"B192","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-021-03843-2","article-title":"Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary","volume":"155","author":"Browne-Farmer","year":"2021","journal-title":"J Neuro-Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-010-1269-9","article-title":"Choroid plexus tumors in children less than 36 months: the Canadian Pediatric Brain Tumor Consortium (CPBTC) experience","volume":"27","author":"Lafay-Cousin","year":"2011","journal-title":"Child's Nervous System"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1097\/01.jnen.0000240464.26005.90","article-title":"Prognostic implications of atypical histologic features in choroid plexus papilloma","volume":"65","author":"Jeibmann","year":"2006","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1159\/000525746","article-title":"Rare case of pediatric disseminated choroid plexus papilloma: literature review and call for reclassification","volume":"57","author":"Mazur-Hart","year":"2022","journal-title":"Pediatr Neurosurg"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2022.03.068","article-title":"Infantile choroid plexus papilloma with multiple peritumoral cysts","volume":"162","author":"Horinouchi","year":"2022","journal-title":"World Neurosurg"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3171\/2014.12.peds14372","article-title":"Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas","volume":"16","author":"Schneider","year":"2015","journal-title":"J Neurosurgery: Pediatr"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-007-9428-x","article-title":"Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors","volume":"85","author":"Wrede","year":"2007","journal-title":"J Neuro-Oncol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00381-012-1912-8","article-title":"Preoperative embolisation of choroid plexus tumours in children: part I\u2014does the reduction of perioperative blood loss affect the safety of subsequent surgery","volume":"29","author":"Haliasos","year":"2013","journal-title":"Child's Nervous System"},{"key":"B200","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11060-021-03942-0","article-title":"Final results of the Choroid Plexus Tumor study CPT-SIOP-2000","volume":"156","author":"Wolff","year":"2022","journal-title":"J Neuro-Oncol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25436","article-title":"Choroid plexus carcinoma in children: the Head Start experience","volume":"62","author":"Zaky","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B202","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pediatrneurol.2015.03.019","article-title":"Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with Malignant brain tumors, the CCG-99703 phase I\/II study. A report from the Children's Oncology Group","volume":"53","author":"Cohen","year":"2015","journal-title":"Pediatr Neurol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-1324","article-title":"Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups","volume":"21","author":"Merino","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae176","article-title":"Activation of Wnt\/\u03b2-catenin signaling is critical for the tumorigenesis of choroid plexus","volume":"27","author":"Ho","year":"2025","journal-title":"Neuro-Oncology"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.04.005","article-title":"Cross-species genomics identifies TAF12, NFYC, and RAD54L as choroid plexus carcinoma oncogenes","volume":"27","author":"Tong","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1874371\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:58:09Z","timestamp":1786708689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1874371\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":205,"alternative-id":["10.3389\/fonc.2026.1874371"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1874371","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1874371"}}